nach oben

Erschienen in:

2014 | OriginalPaper | Buchkapitel

85. Nuclear Receptor Property of E2F1 for Novel Anticancer Drug Discovery

verfasst von : Ning Zhang, Jin Li, Aimin Meng

Erschienen in: Proceedings of the 2012 International Conference on Applied Biotechnology (ICAB 2012)

Verlag: Springer Berlin Heidelberg

Einloggen

Aktivieren Sie unsere intelligente Suche, um passende Fachinhalte oder Patente zu finden.

search-config

KI-gestützte Suche

Aus

Abstract

E2F1, a member of transcription factor superfamily E2F, is similar to nuclear receptors such as estrogen receptor (ER) and peroxisome proliferators-activated receptors (PPARs) in structure and function. However, E2F1 plays a paradoxical role in cancer progression control. Instead of non-transcriptional function, the paradox mainly derives from E2F1 transcriptional function, which determines cell death or survival by different cofactors recruitment. This characteristic of E2F1 establishes itself as a good target for novel anticancer drug discovery and it is promising to develop appropriate small molecules with E2F1 antagonism activity or inverse agonist activity which might be even better for tumor suppression.

Sie haben noch keine Lizenz? Dann Informieren Sie sich jetzt über unsere Produkte:

Springer Professional "Wirtschaft+Technik"

Online-Abonnement

Mit Springer Professional "Wirtschaft+Technik" erhalten Sie Zugriff auf:

über 102.000 Bücher
über 537 Zeitschriften

aus folgenden Fachgebieten:

Automobil + Motoren
Bauwesen + Immobilien
Business IT + Informatik
Elektrotechnik + Elektronik
Energie + Nachhaltigkeit
Finance + Banking
Management + Führung
Marketing + Vertrieb
Maschinenbau + Werkstoffe
Versicherung + Risiko

Jetzt Wissensvorsprung sichern!

Jetzt informieren

Springer Professional "Technik"

Online-Abonnement

Mit Springer Professional "Technik" erhalten Sie Zugriff auf:

über 67.000 Bücher
über 390 Zeitschriften

aus folgenden Fachgebieten:

Automobil + Motoren
Bauwesen + Immobilien
Business IT + Informatik
Elektrotechnik + Elektronik
Energie + Nachhaltigkeit
Maschinenbau + Werkstoffe

Jetzt Wissensvorsprung sichern!

Jetzt informieren

Vorheriges Kapitel Using Water Miscible Ionic Liquid to Improve the Efficiency of 15α-hydroxylation of 13-ethyl-gon-4-en-3,17-dione by Penicillium raistrickii

Nächstes Kapitel MRTF-A Promotes Migration of MCF-7 Breast Cancer Cells via Transactivation of CYR61

Timmers C, Sharma N, Opavsky R et al (2007) E2f1, E2f2 and E2f3 control E2F target expression and cellular proliferation via a p53-dependent negative feedback loop. Mol Cell Biol 27:65–78CrossRef

Wu L, Timmers C, Maiti B et al (2001) The E2F1-3 transcription factors are essential for cellular proliferation. Nature 414:457–462CrossRef

Engelmann D, Pützer BM (2010) Translating DNA damage into cancer cell death-A roadmap for E2F1 apoptotic signalling and opportunities for new drug combinations to overcome chemoresistance. Drug Resist Updates 13:119–131CrossRef

Johnson DG, Degregori J (2006) Putting the oncogenic and tumor suppressive activities of E2F into context. Curr Mol Med 6:731–738

Engelmann D, Pützer BM (2012) The dark side of E2F1: in transit beyond apoptosis. Cancer Res 72:571–575CrossRef

Banerjee D, Schnieders B, Fu JZ et al (1998) Role of E2F1 in chemosensitivity. Cancer Res 58:4292–4296

Dong YB, Yang HL, McMasters KM (2003) E2F1 overexpression sensitizes colorectal cancer cells to camptothecin. Cancer Gene Ther 10:168–178CrossRef

Hao H, Zhou HS, McMasters KM (2009) Chemosensitization of tumor cells: inactivation of nuclear factor-kappa B associated with chemosensitivity in melanoma cells after combination treatment with E2F1 and doxorubicin. Methods Mol Biol 542:301–313

Lammens T, Li J, Leone G et al (2009) Atypical E2Fs: new players in the E2F transcription factor family. Trends Cell Biol 19:111–118CrossRef

10.

DeGregori J, Johnson DG (2006) Distinct and overlapping roles for E2F family members in transcription, proliferation and apoptosis. Curr Mol Med 6:739–748

11.

Rowland BD, Bernards R (2006) Re-evaluating cell cycle regulation by E2Fs. Cell 127:871–874CrossRef

12.

Chris MB, Moray JC (2010) Nuclear Receptors. Springer, New York

13.

Biswas AK, Johnson DG (2012) Transcriptional and nontranscriptional functions of E2F1 in response to DNA damage. Cancer Res 72:3–7

14.

Rubin SM, Gall AL, Zheng N et al (2005) Structure of the Rb C-terminal domain bound to E2F1-DP1: a mechanism for phosphorylation-induced E2F release. Cell 123:1093–1106CrossRef

15.

Slansky JE, Farnham PJ (1996) Introduction to the E2F family: protein structure and gene regulation. Curr Top Microbiol Immunol 208:1–30CrossRef

16.

Cress WD, Nevins JR (1996) A role for a bent DNA structure in E2F-mediated transcription activation. Mol Cell Biol 16(5):2119–2127

17.

Lazzerini Denchi E, Helin K (2005) E2F1 is crucial for E2F-dependent apoptosis. EMBO Rep 6:661–668CrossRef

18.

Ren B, Cam H, Takahashi Y et al (2002) E2F integrates cell cycle progression with DNA repair, replication, and G2/M checkpoints. Genes Dev 16:245–256CrossRef

19.

Alonso MM, Alemany R, Fueyo J et al (2008) E2F1 in gliomas: a paradigm of oncogene addiction. Cancer Lett 263:157–163CrossRef

20.

Feldstein O, Ben-Hamo R, Bashari D et al (2012) RBM38 is a direct transcriptional target of E2F1 that limits E2F1 induced proliferation. Mol Cancer Res 0(9):1169–1177

21.

Wu Z, Yu Q (2009) E2F1-mediated apoptosis as a target of cancer therapy. Curr Mol Pharmacol 2:149–160

22.

Freeman SN, Ma Y, Cress WD (2008) RhoBTB2 (DBC2) is a mitotic E2F1 target gene with a novel role in apoptosis. J Biol Chem 283:2353–2362CrossRef

23.

Lonard DM, O’Malley BW (2012) Nuclear receptor coregulators: modulators of pathology and therapeutic targets. Nat Rev Endocrinol 8:598–604CrossRef

24.

Martin K, Trouche D, Hagemeier C et al (1995) Stimulation of E2F1/DP1 transcriptional activity by MDM2 oncoprotein. Nature 375:691–694CrossRef

25.

Verhaegen M, Checinska A, Riblett MB et al (2012) E2F1 dependent oncogenic addiction of melanoma cells to MDM2. Oncogene 31:828–841CrossRef

26.

Revenko AS, Kalashnikova EV, Gemo AT et al (2010) Chromatin loading of E2F-MLL complex by cancer-associated coregulator ANCCA via reading a specific histone mark. Mol Cell Biol 30:5260–5272CrossRef

27.

Brand TM, Iida M, Li C et al (2011) The nuclear epidermal growth factor receptor signaling network and its role in cancer. Discovery Med 12:419–432

28.

Hanada N, Lo HW, Day CP et al (2006) Coregulation of B-Myb expression by E2F1 and EGF receptor. Mol Carcinog 45:10–17CrossRef

29.

Mussi P, Yu C, O’Malley BW et al (2006) Stimulation of steroid receptor coactivator 3 (SRC-3) gene overexpression by a positive regulatory loop of E2F1 and SRC-3. Mol Endocrinol 20:3105–3119CrossRef

30.

Louie MC, Zou JX, Rabinovich A et al (2004) ACTR/AIB1 functions as an E2F1 coactivator to promote breast cancer cell proliferation and antiestrogen resistance. Mol Cell Biol 24:5157–5171CrossRef

31.

Watabe Y, Nazuka N, Tezuka M et al (2010) Aryl hydrocarbon receptor functions as a potent coactivator of E2F1-dependent trascription activity. Biol Pharm Bull 33:389–397CrossRef

32.

Marlowe JL, Fan Y, Chang X et al (2008) The aryl hydrocarbon receptor binds to E2F1 and inhibits E2F1 induced apoptosis. Mol Biol Cell 19:3263–3271CrossRef

33.

Knight JR, Milner J (2012) SIRT1, metabolism and cancer. Curr Opin Oncol 24:68–75CrossRef

34.

Wang C, Chen L, Hou X et al (2006) Interactions between E2F1 and SirT1 regulate apoptotic response to DNA damage. Nat Cell Biol 8:1025–1031CrossRef

35.

Pediconi N, Guerrieri F, Vossio S et al (2009) hSirT1-dependent regulation of the PCAF-E2F1-p73 apoptotic pathway in response to DNA damage. Mol Cell Biol 29:1989–1998CrossRef

36.

Julian LM, Palander O, Seifried LA et al (2008) Characterization of an E2F1 specific binding domain in pRB and its implications for apoptotic regulation. Oncogene 27:1572–1579CrossRef

37.

Dick FA, Dyson N (2003) pRB contains an E2F1 specific binding domain that allows E2F1 induced apoptosis to be regulated separately from other E2F activities. Mol Cell 12:639–649CrossRef

38.

O’Connor RJ, Schaley JE, Feeney G et al (2001) The p107 tumor suppressor induces stable E2F DNA binding to repress target promoters. Oncogene 20:1882–1891CrossRef

39.

Dai Y, Hamm TE, Dent P et al (2006) Cyclin D1 overexpression increases the susceptibility of human U266 myeloma cells to CDK inhibitors through a process involving p130-, p107- and E2F-dependent S phase entry. Cell Cycle 5:437–446CrossRef

40.

Shackleford TJ, Claret FX (2010) JAB1/CSN5: a new player in cell cycle control and cancer. Cell Div 18:26CrossRef

41.

Lu H, Liang X, Issaenko OA et al (2011) Jab1/CSN5 mediates E2F dependent expression of mitotic and apoptotic but not DNA replication targets. Cell Cycle 10:3317–3326CrossRef

42.

Hallstrom TC, Nevins JR (2006) Jab1 is a specificity factor for E2F1 induced apoptosis. Genes Dev 20:613–623CrossRef

43.

Docquier A, Harmand PO, Fritsch S et al (2010) The transcriptional coregulator RIP140 represses E2F1 activity and discriminates breast cancer subtypes. Clin Cancer Res 16:2959–2970CrossRef

44.

Chapman EJ, Knowles MA (2009) Necdin: a multi functional protein with potential tumor suppressor role? Mol Carcinog 48:975–981CrossRef

45.

Taniura H, Taniguchi N, Hara M et al (1998) Necdin, a postmitotic neuron-specific growth suppressor, interacts with viral transforming proteins and cellular transcription factor E2F1. J Biol Chem 273:720–728CrossRef

46.

Papaioannou M, Melle C, Baniahmad A (2007) The coregulator Alien. Nucl Recept Signal 5:e008

47.

Tenbaum SP, Papaioannou M, Reeb CA et al (2007) Alien inhibits E2F1 gene expression and cell proliferation. Biochim Biophys Acta 1773:1447–1454CrossRef

48.

Hong W, Li J, Wang B et al (2011) Epigenetic involvement of Alien/ESET complex in thyroid hormone-mediated repression of E2F1 gene expression and cell proliferation. Biochem Biophys Res Commun 415:650–655CrossRef

49.

Li Y, Sun X, LaMont JT et al (2003) Selective killing of cancer cells by beta-lapachone: direct checkpoint activation as a strategy against cancer. Proc Natl Acad Sci U S A 100:2674–2678CrossRef

50.

Choi YH, Kang HS, Yoo MA (2003) Suppression of human prostate cancer cell growth by beta-lapachone via down-regulation of pRB phosphorylation and induction of Cdk inhibitor p21(WAF1/CIP1). J Biochem Mol Biol 36:223–229CrossRef

51.

Ambrosini G, Sambol EB, Carvajal D et al (2007) Mouse double minute antagonist Nutlin-3a enhances chemotherapy induced apoptosis in cancer cells with mutant p53 by activating E2F1. Oncogene 26:3473–3481CrossRef

52.

Kitagawa M, Aonuma M, Lee SH et al (2008) E2F1 transcriptional activity is a critical determinant of Mdm2 antagonist-induced apoptosis in human tumor cell lines. Oncogene 27:5303–5314CrossRef

53.

Yu B, Lane ME, Wadler S (2002) SU9516, a cyclin dependent kinase 2 inhibitor, promotes accumulation of high molecular weight E2F complexes in human colon carcinoma cells. Biochem Pharmacol 64:1091–1100CrossRef

54.

Lane ME, Yu B, Rice A et al (2001) A novel cdk2-selective inhibitor, SU9516, induces apoptosis in colon carcinoma cells. Cancer Res 61:6170–6177

55.

Lee SH, Park C, Jin CY et al (2008) Involvement of extracellular signal-related kinase signaling in esculetin induced G1 arrest of human leukemia U937 cells. Biomed Pharmacother 62:723–729CrossRef

56.

Shi Y, Yang S, Troup S et al (2011) Resveratrol induces apoptosis in breast cancer cells by E2F1-mediated up-regulation of ASPP1. Oncol Rep 25:1713–1719

57.

Oh WK, Cho KB, Hien TT et al (2010) Amurensin G, a potent natural SIRT1 inhibitor, rescues doxorubicin responsiveness via down regulation of multidrug resistance. Mol Pharmacol 78:855–864CrossRef

58.

Kim JA, Kim MR, Kim O et al (2012) Amurensin G inhibits angiogenesis and tumor growth of tamoxifen resistant breast cancer via Pin1 inhibition. Food Chem Toxicol 50:3625–3634CrossRef

59.

Zhao Y, Tan J, Zhuang L et al (2005) Inhibitors of histone deacetylases target the Rb-E2F1 pathway for apoptosis induction through activation of proapoptotic protein Bim. Proc Natl Acad Sci U S A 102:16090–16095CrossRef

60.

Muller PA, Vousden KH, Norman JC (2011) P53 and its mutants in tumor cell migration and invasion. J Cell Biol 192:209–218CrossRef

61.

Gordon GM, Du W (2011) Targeting Rb inactivation in cancers by synthetic lethality. Am J Cancer Res 1:773–786

Titel: Nuclear Receptor Property of E2F1 for Novel Anticancer Drug Discovery
verfasst von: Ning Zhang
Jin Li
Aimin Meng
Verlag: Springer Berlin Heidelberg
Buch: Proceedings of the 2012 International Conference on Applied Biotechnology (ICAB 2012)
Print ISBN: 978-3-642-37921-5

Electronic ISBN: 978-3-642-37922-2

Copyright-Jahr: 2014
DOI: https://doi.org/10.1007/978-3-642-37922-2_85

Premium Partner

Marktübersichten

Die im Laufe eines Jahres in der „adhäsion“ veröffentlichten Marktübersichten helfen Anwendern verschiedenster Branchen, sich einen gezielten Überblick über Lieferantenangebote zu verschaffen.

Zur Marktübersicht